StemCells, Inc. to Participate at the Inaugural World Medical Innovation Forum
April 27 2015 - 8:00AM
StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn,
CEO of StemCells, Inc., will participate on a panel moderated by
Alice Park, writer for TIME Magazine, at the inaugural World
Medical Innovation Forum to be held in Boston, April 27-29, 2015.
The expert panel members will discuss central nervous system
therapies that use healthy cells, tissues or organs—or those
created with 3D bioprinters—to replace damaged ones. The panel is
scheduled for 9:25 a.m. EDT on Tuesday, April 28, in the Biogen
Ballroom at The Westin Copley Place, 10 Huntington Ave, Boston.
About World Medical Innovation Forum
Neurosciences
The World Medical Innovation Forum features CEOs of
industry-leading multinational medical companies, Partners
HealthCare top clinicians and scientists—all Harvard Medical School
faculty members—and global technology leaders. Join 1,000
international innovation decision-makers and be briefed on the
state of the art in neuroscience technology, care and research
directly from the CEOs bringing game-changing products to market,
world-class clinicians delivering the highest-quality care and the
scientists rapidly propelling this crucial field forward through
their CNS insights and discoveries. Additionally, the industry-wide
issues driving investment, application and reimbursement of
innovation during this period of profound transformation in
healthcare will be debated.
The inaugural World Medical Innovation Forum will be held in
Boston April 27-29, 2015. Current and emerging approaches to
diagnosing and caring for neurologic and psychiatric disorders will
be highlighted, including multiple sclerosis, Alzheimer's disease,
Parkinson's disease, depression, schizophrenia, autism, stroke and
sleep disorders. Also, game-changing diagnostic tools and
therapeutic interventions will be presented, including genome
editing, gene therapy, neurostimulation, neuroregeneration,
population management, neuroimaging and novel biomarkers.
The World Forum is organized around one clinical field per
year—neurosciences in 2015 followed by cancer in 2016. The annual
Forum provides attendees and policy makers with actionable insights
into the torrent of new technology in the neurosciences and the
swiftly evolving business of health care innovation. Attendees are
senior executives of large companies, investors, entrepreneurs and
officers of venture-backed companies, business-minded clinicians
and investigators, government principals and dealmakers.
Participants include a significant complement of international
leaders and organizations.
About StemCells, Inc.
StemCells, Inc. is currently engaged in clinical development of
its HuCNS-SC (purified human neural stem cells) platform
technology, as a potential treatment for diseases and disorders of
the central nervous system. Interim data from the Company's Phase
I/II clinical trial in thoracic spinal cord injury (SCI) shows
measurable gains involving multiple sensory modalities and segments
in half of the subjects, two of whom converted from complete injury
(AIS A) to incomplete injury (AIS B), post-transplant. Enrollment
has recently commenced in the Company's Phase II clinical trial in
cervical SCI. StemCells, Inc. has also completed enrollment and
treatment in its Phase I/II clinical trial in geographic atrophy of
age-related macular degeneration (GA-AMD), the most severe form of
dry AMD, which is the leading cause of blindness in the elderly.
Interim results for those subjects with 12 month follow-up post
transplantation of HuCNS-SC cells into the eye, showed a reduction
in the rate of disease progression as compared to the control
(untreated) eye and to the expected natural history of the disease.
In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD),
a fatal myelination disorder in children, the Company showed
preliminary evidence of progressive and durable donor-derived
myelination in all four patients transplanted with HuCNS-SC cells.
Further information about StemCells, Inc. is available at
http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press
release constitutes forward-looking statements within the meaning
of the U.S. securities laws, and is subject to the safe harbors
created therein. These forward-looking statements speak only as of
the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2014 and
in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Greg Schiffman
StemCells, Inc.
Chief Financial Officer
(510) 456-4128
Lena Evans
Russo Partners
(212) 845-4262
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024